Drug Information

Drug General Information
Drug ID
D0B8MS
Former ID
DND000011
Drug Name
MEDI-547
Synonyms
MedImmune, MedImmune/AstraZeneca
Drug Type
Antibody
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [522493]
Company
AstraZeneca
Target and Pathway
Target(s) Ephrin type-A receptor 2 Target Info [543506]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
PI3K-Akt signaling pathway
Axon guidance
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database EphrinA-EPHA pathway
Arf6 signaling events
Direct p53 effectors
EPHA forward signaling
Stabilization and expansion of the E-cadherin adherens junction
EPHA2 forward signaling
Reactome EPH-Ephrin signaling
EPHA-mediated growth cone collapse
EPH-ephrin mediated repulsion of cells
WikiPathways NRF2 pathway
References
Ref 522493ClinicalTrials.gov (NCT00796055) Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors. U.S. NationalInstitutes of Health.
Ref 543506(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822).

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.